{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:08:55Z","timestamp":1791428935160,"version":"4.3.3"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["F32DC017342"],"award-info":[{"award-number":["F32DC017342"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK106448"],"award-info":[{"award-number":["K23DK106448"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL144566"],"award-info":[{"award-number":["R01HL144566"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI143887"],"award-info":[{"award-number":["R01AI143887"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI (ICPI-AKI) is emerging as an increasingly frequent cause of AKI in patients with cancer, and poses unique diagnostic and management challenges to clinicians who care for these patients. In this review, we describe the incidence and risk factors for ICPI-AKI, including proton pump inhibitor use, CKD, and combination immunotherapy. We discuss the limitations of the various definitions used for ICPI-AKI in prior studies, and propose a novel classification system (definite, probable, and possible ICPI-AKI) that recognizes the diagnostic uncertainty inherent in many cases. We discuss the key clinicopathologic features and treatment strategies for ICPI-AKI, including the role of kidney biopsy versus empirical treatment with steroids. We also explore the under-studied area of ICPI use in the setting of solid organ transplantation, where nephrologists and oncologists must balance the risk of rejection versus treating the underlying malignancy. Finally, we summarize existing data on the role of ICPI rechallenge after an episode of ICPI-AKI.<\/jats:p>","DOI":"10.34067\/kid.0000852019","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T16:59:23Z","timestamp":1582822763000},"page":"130-140","source":"Crossref","is-referenced-by-count":91,"title":["Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020"],"prefix":"10.34067","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank B.","family":"Cortazar","sequence":"additional","affiliation":[{"name":"New York Nephrology Vasculitis and Glomerular Center, Albany, New York; and"},{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo V.","family":"Riella","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2017.12.007","article-title":"Immune checkpoint inhibitors for metastatic bladder cancer","volume":"64","author":"Massari","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","article-title":"Immunotherapy for the treatment of urothelial carcinoma","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S1470-2045(16)30441-7","article-title":"Checkpoint inhibitors: A new standard of care for advanced merkel cell carcinoma?","volume":"17","author":"Hauschild","year":"2016","journal-title":"Lancet Oncol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"B19-20230821","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B21-20230821","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. [published online ahead of print January 2, 2020]","author":"Cortazar","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ni.2037","article-title":"The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells","volume":"12","author":"Ise","year":"2011","journal-title":"Nat Immunol"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.immuni.2006.06.009","article-title":"T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity","volume":"25","author":"Zehn","year":"2006","journal-title":"Immunity"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.it.2015.12.005","article-title":"Re-examining the nature and function of self-reactive T cells","volume":"37","author":"Richards","year":"2016","journal-title":"Trends Immunol"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993-2011: A case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.2014.74","article-title":"A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use","volume":"86","author":"Blank","year":"2014","journal-title":"Kidney Int"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B40-20230821","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B41-20230821","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: A Report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B42-20230821","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma [published correction appears in Clin Kidney J 9: 649, 2016]","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"B43-20230821","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B44-20230821","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonz\u00e1lez","year":"2008","journal-title":"Kidney Int"},{"issue":"Suppl","key":"B45-20230821","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1200\/jco.2009.27.15_suppl.9037","article-title":"Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity","volume":"27","author":"Amin","year":"2009","journal-title":"J Clin Oncol"},{"key":"B46-20230821","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12032-010-9606-0","article-title":"Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy","volume":"28","author":"Harmankaya","year":"2011","journal-title":"Med Oncol"},{"key":"B47-20230821","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B48-20230821","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ckj\/sfx122","article-title":"Risk factors associated with post-kidney transplant malignancies: An article from the Cancer-Kidney International Network","volume":"11","author":"Sprangers","year":"2018","journal-title":"Clin Kidney J"},{"key":"B49-20230821","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun"},{"key":"B50-20230821","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B51-20230821","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.13786","article-title":"Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy","volume":"16","author":"Boils","year":"2016","journal-title":"Am J Transplant"},{"key":"B52-20230821","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant"},{"key":"B53-20230821","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","author":"Herz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B54-20230821","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.transproceed.2019.08.002","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with metastatic cancer post solid organ transplantation: A case report and review of the literature","volume":"51","author":"Wong","year":"2019","journal-title":"Transplant Proc"},{"key":"B55-20230821","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"key":"B56-20230821","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/j.transproceed.2016.07.019","article-title":"Renal allograft failure after ipilimumab therapy for metastatic melanoma: A case report and review of the literature","volume":"48","author":"Jose","year":"2016","journal-title":"Transplant Proc"},{"key":"B57-20230821","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"B58-20230821","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B59-20230821","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B60-20230821","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"B61-20230821","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"B62-20230821","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12882-018-1003-5","article-title":"PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report","volume":"19","author":"Goldman","year":"2018","journal-title":"BMC Nephrol"},{"key":"B63-20230821","article-title":"Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients [published online ahead of print August 9, 2019]","author":"Venkatachalam","journal-title":"Transplantation"},{"key":"B64-20230821","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature [published correction appears in J Immunother Cancer 7: 158, 2019]","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B65-20230821","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/TP.0000000000000169","article-title":"Co-inhibitory pathways and their importance in immune regulation","volume":"98","author":"Murakami","year":"2014","journal-title":"Transplantation"},{"key":"B66-20230821","doi-asserted-by":"crossref","first-page":"c570","DOI":"10.1136\/bmj.c570","article-title":"Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: Population based retrospective cohort study","volume":"340","author":"van Leeuwen","year":"2010","journal-title":"BMJ"},{"key":"B67-20230821","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"B68-20230821","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/ajt.14619","article-title":"Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"key":"B69-20230821","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B70-20230821","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000852019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:56:39Z","timestamp":1786478199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000852019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000852019","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}